Browsing by Author "Yurdaydin, Cihan"
Now showing items 1-13 of 13
-
96 weeks of pegylated-Interferon- alpha-2? plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study
Wedemeyer, Heiner; Yurdaydin, Cihan; Ernst, Stefanie; Caruntu, Florin A.; Curescu, Manuela G.; Yalcin, Kendal; Akarca, Ulus S. (Wiley-Blackwell, 2013)[Abstract Not Available] -
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-?2a treatment
Mederacke, Ingmar; Yurdaydin, Cihan; Dalekos, George N.; Bremer, Birgit; Erhardt, Andreas; Cakaloglu, Yilmaz; Yalcin, Kendal (Int Medical Press Ltd, 2012)Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected ... -
Anti-HDV-IgM levels as a marker of disease activity and response to pegylated Interferon-? based therapy in hepatitis delta
Wranke, Anika; Yurdaydin, Cihan; Heidrich, Benjamin; Ernst, Stefanie; Koch, Armin; Serrano, Beatriz Calle; Caruntu, Florin A. (Wiley-Blackwell, 2013)[Abstract Not Available] -
BASELINE ALT LEVELS BUT NOT HDV-RNA LEVELS ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT OF DELTA HEPATITIS: DATA FROM THE HIDIT-1 TRIAL
Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; Erhardi, Annette; Cakaloglu, Yilmaz; Yalcin, Kendal; Gurel, Selim (John Wiley & Sons Inc, 2008)[Abstract Not Available] -
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus adevofir dipivoxil vs. pegylated interferon-alfa-2a plus placebo vs. adevofir dipivoxil for the treatment of chronic delta hepatitis: The hep-net/international delta hepatitis intervention trial (HID-IT)
Yurdaydin, Cihan; Wedemeyer, Heiner; Dalekos, George; Erhardt, Alexander; Cakaloglu, Ya; Degertekin, Ha; Gurel, Sa. (John Wiley & Sons Inc, 2006)[Abstract Not Available] -
A novel non-invasive fibrosis score based on cytokines and clinical parameters for the use in chronic hepatitis delta
Heidrich, Benjamin; Wranke, Anika; Yurdaydin, Cihan; Stift, Judith; Caruntu, Florin A.; Curescu, Manuela G.; Yalcin, Kendal (Wiley-Blackwell, 2013)[Abstract Not Available] -
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
Wedemeyer, Heiner; Yurdaydin, Cihan; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalcin, Kendal; Akarca, Ulus S. (Elsevier Sci Ltd, 2019)Background Hepatitis D is the most severe form of chronic viral hepatitis. Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25-30% of patients only. Whether prolonged therapy with peginterferon ... -
Pegylated interferon-alfa-2A plus adefovir combination therapy is superior to pegylated interferon-alfa-2A alone or adefovir monotherapy in reducing HBsAg levels in hdvcoinfected patients with low HBV viremia
Wedemeyer, Heiner; Yurdaydin, Cihan; Zachou, Kalliopi; Erhardt, Alexander; Drebber, Ulrike; Cakaloglu, Ya; Degertekin, Ha (John Wiley & Sons Inc, 2006)[Abstract Not Available] -
Pegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study
Yurdaydin, Cihan; Wedemeyer, Heiner; Caruntu, Florin A.; Curescu, Manuela G.; Yalcin, Kendal; Akarca, Ulus S.; Gurel, Selim (Wiley-Blackwell, 2012)[Abstract Not Available] -
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial
Dinkelborg, Katja; Kahlhoefer, Julia; Doerge, Petra; Yurdaydin, Cihan; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G. (Wiley, 2023)Background & AimsInfection with the hepatitis D virus (HDV) causes the most severe form of viral hepatitis with a high risk to develop clinical complications of liver disease. In addition, hepatitis delta has been shown ... -
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis
Zachou, Kalliopi; Yurdaydin, Cihan; Drebber, Uta; Dalekos, George N.; Erhardt, Andreas; Cakaloglu, Yilmaz; Degertekin, Halil (Wiley, 2010)Background: Hepatitis delta virus (HDV) causes severe liver disease. Aims: To investigate the quantitative HDV-RNA, HBsAg and hepatitis B virus (HBV)DNA levels in correlation to histological, biochemical and demographical ... -
Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey
Degertekin, Halil; Yalcin, Kendal; Yakut, Mustafa; Yurdaydin, Cihan (Wiley, 2008)Background: Recent reports suggest a decline of delta hepatitis (DH) in the West as well as in the Far East. Aim: To study the DH seroepidemiology in Turkey. Methods: Statistical power analysis was utilized based on data ... -
A transient early HBV-DNA increase during PEG-IFN? therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction
Anastasiou, Olympia E.; Yurdaydin, Cihan; Maasoumy, Benjamin; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalcin, Kendal (Wiley, 2021)HBV-DNA levels are low or even undetectable in the majority HDV-infected patients. The impact of PEG-IFN alpha on HBV-DNA kinetics in HDV-infected patients has not been studied in detail. We analysed data of a prospective ...
